Time BioVentures is an early-stage life sciences and healthcare venture capital firm that focuses on financing "iconoclastic founders" who aim to reinvent the healthcare system. Their strategy involves investing in "game-changing innovations" such as radically better drugs, diagnostics, research tools, devices, and care delivery models, rather than incremental improvements.
58% of their portfolio is in Healthcare. Their most common stage is series-a (42% of deals). Average disclosed round size is $51.6M (across 11 rounds with reported amounts).
Portfolio
12
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
2
Team
DL
Dr. Lue Sun
Partner, Co-CIO
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Commons Clinic | Series B | $26M | Jun 2025 |
 Phantom Neuro | Series A | $19M | Apr 2025 |
 Conceivable Life Sciences | Series A | $18M | Jan 2025 |
 Rivermark Medical | Series C | $30M | Oct 2024 |
| Commons Clinic | Series A | $19.5M | Oct 2023 |
 BillionToOne | Series C | $48.5M | Dec 2022 |
| Phantom Neuro | Seed | $6M | Oct 2022 |
| BillionToOne | Series C | $125M | Mar 2022 |
 NanoMosaic | Series A | $40.8M | Dec 2021 |
| IIterative Scopes | Series A | $30M | Aug 2021 |
 Neuralink | Series C | $205M | Jul 2021 |
| IIterative Scopes | Unknown | — | Dec 2020 |
Top Co-Investors
RA Capital Management3 shared
Floating Point2 shared
Courtside Ventures2 shared
Breakout Ventures2 shared
Draper Associates2 shared
LionBird Ventures2 shared
Baillie Gifford2 shared
Norwest Venture Partners2 shared
Adams Street2 shared
Hummingbird Ventures2 shared
Neotribe2 shared
Libertus2 shared
Muse Capital1 shared
SteelSky Ventures1 shared
Obvious Ventures1 shared
Eli Lilly1 shared
Johnson & Johnson Innovation1 shared
Breyer Capital1 shared
Vy Capital1 shared
GV (Google Ventures)1 shared
Last updated: 8 March 2026